Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

Table 1 Demographic and clinical characteristics of melanoma patients on immunotherapy

Characteristic	All patients (n = 27)	No progression (n = 15)	Any progression (n = 12)	p ^a
Age (years)^b, mean ± SD	70.3 ± 11.9	66.6 ± 12.5	74.9 ± 9.6	< 0.0001
Male, %	77.8	73.3	83.3	0.66
White, %	96.3	100	91.7	0.44
BMI (kg/m²)^b, mean ± SD	27.5 ± 4.8	28.4 ± 4.3	26.5 ± 5.3	< 0.0001
Melanoma type, %				0.02
Nodular	18.5	6.7	33.3
Acral lentiginous	3.7	0	8.3
Superficial spreading	3.7	0	8.3
Desmoplastic	3.7	0	8.3
NOS/missing	70.4	93.3	41.7
Driver mutation, %				0.83
NRAS	18.5	13.3	25
BRAF	25.9	33.3	16.7
None	29.6	26.7	33.3
Missing	25.9	26.7	25
Stage^b, %				0.68
III	33.3	40	25
IV	66.7	60	75
LDH > 618 U/L^b, %	7.4	0	16.7	0.22
Sites of metastasis^b,c, %				0.21
0	40.7	53.3	25
1–2	33.3	33.3	33.3
≥ 3	25.9	13.3	41.7
Immunotherapy type, %				0.44
Anti-PD-1	51.9	46.7	58.3
Anti-CTLA-4	3.7	0	8.3
Anti-PD-1/anti-CTLA-4	44.4	53.3	33.3
Antibiotics in prior 6 months, %	55.6	60	50	0.71

^ap value for difference by progression status, from Wilcoxon rank-sum test for continuous variables or Fisher’s exact test for categorical variables
^bCharacteristic prior to immunotherapy start (not at diagnosis)
^cPatients with 0 sites of metastasis were resected with no evidence of disease and were being treated adjuvantly

ISSN: 1756-994X